CN113018235A - High-efficiency allergy-relieving and anti-inflammatory composition - Google Patents
High-efficiency allergy-relieving and anti-inflammatory composition Download PDFInfo
- Publication number
- CN113018235A CN113018235A CN202110203870.9A CN202110203870A CN113018235A CN 113018235 A CN113018235 A CN 113018235A CN 202110203870 A CN202110203870 A CN 202110203870A CN 113018235 A CN113018235 A CN 113018235A
- Authority
- CN
- China
- Prior art keywords
- extract
- relieving
- allergy
- inflammatory composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 30
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 29
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 28
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000000284 extract Substances 0.000 claims abstract description 47
- -1 honokiol compound Chemical class 0.000 claims abstract description 26
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940038580 oat bran Drugs 0.000 claims abstract description 24
- 239000011701 zinc Substances 0.000 claims abstract description 24
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 24
- 238000000855 fermentation Methods 0.000 claims abstract description 19
- 230000004151 fermentation Effects 0.000 claims abstract description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 18
- 240000006053 Garcinia mangostana Species 0.000 claims abstract description 17
- 235000017048 Garcinia mangostana Nutrition 0.000 claims abstract description 17
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 claims abstract description 16
- 235000020737 peppermint extract Nutrition 0.000 claims abstract description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000002537 cosmetic Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 229940116707 mentha piperita extract Drugs 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 7
- 229940093541 dicetylphosphate Drugs 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 229950003429 sorbitan palmitate Drugs 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940102465 ginger root Drugs 0.000 claims description 3
- 239000001841 zingiber officinale Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 2
- 230000003389 potentiating effect Effects 0.000 claims 4
- 239000001534 FEMA 4201 Substances 0.000 claims 1
- 235000004357 Mentha x piperita Nutrition 0.000 claims 1
- 241001479543 Mentha x piperita Species 0.000 claims 1
- 210000004727 amygdala Anatomy 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 claims 1
- 239000001771 mentha piperita Substances 0.000 claims 1
- 229940060184 oil ingredients Drugs 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 38
- 238000012360 testing method Methods 0.000 description 16
- 208000003251 Pruritus Diseases 0.000 description 14
- 230000002757 inflammatory effect Effects 0.000 description 14
- 206010015150 Erythema Diseases 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 11
- 230000007803 itching Effects 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 7
- 230000002421 anti-septic effect Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 240000003549 Brabejum stellatifolium Species 0.000 description 6
- 235000013698 Brabejum stellatifolium Nutrition 0.000 description 6
- 239000008168 almond oil Substances 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229940049964 oleate Drugs 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 230000036555 skin type Effects 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- JVDHWXLTNDKLIZ-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CCCNC(N)=N JVDHWXLTNDKLIZ-WCCKRBBISA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- QTDMGAWIBXJNRR-UHFFFAOYSA-N Mangostin Natural products CC(=CCc1c(O)cc2Oc3cc(C)c(O)c(CC=C(C)C)c3C(=O)c2c1O)C QTDMGAWIBXJNRR-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- GNRIZKKCNOBBMO-UHFFFAOYSA-N alpha-mangostin Chemical compound OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3OC2=C1 GNRIZKKCNOBBMO-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940078492 ppg-17 Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of skin care, and particularly discloses a high-efficiency allergy-relieving and anti-inflammatory composition which is characterized by comprising a hydrolytic mangosteen extract, a yeast/zinc fermentation product, a magnolol and honokiol compound, an oat bran extract, a peppermint extract and a ginger root extract.
Description
Technical Field
The invention relates to the technical field of skin care, in particular to a high-efficiency allergy-relieving and anti-inflammatory composition.
Background
According to survey, the number of people with dermatitis, allergy and other problems of the skin is gradually increased year by year, various factors such as seasonal changes, dust, particles, harmful substances in the air, high-intensity work, improper use of skin care products and the like easily cause a plurality of skin allergy and inflammation problems, such as pimples, skin flushing, redness, itching, pricking pain, burning, itching, desquamation and the like, and particularly cosmetics used on each face every day are factors which most directly influence the skin state.
Disclosure of Invention
The invention aims to provide a high-efficiency allergy-relieving and anti-inflammatory composition aiming at the prior technical current situation, the composition is prepared by compounding a plurality of natural plant extracts, various components are reasonably combined and matched for use, the influence of external factors and irritant functional raw materials on skin is efficiently solved in three directions of inhibiting the generation of inflammatory factors, inhibiting the release of inflammatory mediators and providing peptides required by the skin, and a skin barrier is established, so that the allergy-relieving and anti-inflammatory effects are achieved.
In order to achieve the purpose, the invention adopts the following technical scheme:
a high-efficiency allergy-relieving and anti-inflammatory composition is characterized by comprising a hydrolyzed mangosteen extract, a yeast/zinc fermentation product, a magnolol and honokiol compound, an oat bran extract, a peppermint extract and a ginger root extract.
In the invention, the extract of the hydrolyzed mangosteen is xanthone and tannic acid extracted from mangosteen shells, and research shows that mangostin serving as an anti-inflammatory substance can effectively inhibit the release of an inflammation chemical mediator PGE2 and inhibit COX-2 gene activation.
Zinc is a trace element necessary for cell growth, development and differentiation, and can help more than 300 enzymes to maintain the structure and function of the enzymes, and plays an important role in repairing and protecting skin, the lack of zinc can cause the problems of skin dryness, acne, chap and the like, the zinc can inhibit the expression of keratinocyte integrin, regulate the production of TNF-a and IL-6 and reduce the production of inflammatory mediators, however, inorganic zinc has irritation to the skin, the yeast/zinc fermentation product of the invention is generated by yeast strains through a special fermentation process, has small molecules and strong permeability, contains various active substances such as polypeptide, amino acid, vitamin, polysaccharide and the like necessary for the skin, zinc is added in the fermentation process, the zinc and the amino acid exist in a chelating form and are converted into an organic form, the stimulation of the inorganic zinc to the skin is effectively reduced, and the yeast/zinc fermentation product has a long-acting anti-inflammatory effect, and is suitable for skin care treatment of sensitive and irritant skin.
The magnolol and honokiol compound is high-purity hydroxylated biphenyl molecules extracted from magnolia officinalis trees, and has strong anti-inflammatory and anti-oxidation effects. They may inhibit NF-KB factors by inactivating LKB kinase, thereby reducing inflammation. Magnolol and honokiol also reduce the production of important inflammatory mediators, such as interleukin-8 and tumor necrosis factor (TNF-alpha), due to the inhibitory effect on NF-KB factor.
The hydrolytic mangosteen extract, the yeast/zinc fermentation product, and the magnolol and honokiol compound are compatible and synergistic, and can effectively prevent and treat skin irritation, control inflammation and improve skin discomfort.
The oat bran extract disclosed by the invention mainly contains phenolic oat alkaloids, and the oat bran extract can be used for regulating and controlling inflammatory skin through the following two aspects: 1) by reducing histamine release from mast cells, itch, edema, erythema production are reduced; 2) the production of proinflammatory factors IL-6, IL-8 and MCP-1 is inhibited by inhibiting the activity of IL-1 beta subunit. Elevated concentrations of the proinflammatory factors IL-6, IL-8 and MCP-1 promote activation of NF-. kappa.B. Specifically, the IL-1 beta subunit promotes the transport efficiency of NF-kappa B to cell nucleus by the DNA binding activity of the NF-kappa B subunit rho 50, and increases the concentration of the NF-kappa B. The oat bran extract can inhibit the activation of NF-kB and reduce inflammation by inhibiting the activity of IL-1 beta subunit. Inflammatory skin is comprehensively regulated and controlled through two aspects of cells and inflammatory immunity.
The mentha piperita extract is rich in mint leaf flavanone, reduces the generation of prostaglandin E2 by inhibiting the release of main interleukin-1 alpha, 1L-8, reduces the release of inflammatory transmission molecules such as histamine generated by mast cells, regulates skin microcirculation and limits inflammatory symptoms; secondly, the peppermint extract also stimulates beta-lactocin- "pleasant" neuropeptides to participate in pain control and promote skin comfort and health. By regulating the generation of cell mediators involved in skin allergic reaction, the generation of inflammatory phenomena is reduced.
The ginger root extract is rich in gingerol, ginger protease and various volatile oils, and has the effects of resisting bacteria and promoting blood circulation on the surface of skin; the ginger root extract inhibits the secondary reaction of inflammation by modulating lipid mediators, inhibits COX-2 and PGE-2, and prevents redness and erythema.
The skin care product is compounded by multiple natural plant extracts, multiple components interact with each other, the influence of external factors and irritant functional raw materials on the skin is efficiently solved from three directions of inhibiting the generation of inflammatory factors, inhibiting the release of inflammatory mediators and providing peptides required by the skin, and a skin barrier is established, so that the effects of high efficiency, allergy relief and inflammation resistance are achieved.
Preferably, the high-efficiency allergy-relieving and anti-inflammatory composition comprises the following components in percentage by mass:
0.0045 to 0.33 percent of hydrolyzed mangosteen extract;
0.001-0.18% of yeast/zinc fermentation product;
0.001-0.18% of a magnolol and honokiol compound;
0.1-10% of oat bran extract;
0.1-7.0% of peppermint extract;
0.1-6.0% of ginger root extract;
the balance is the common external preparation base in cosmetics or dermatology.
The externally-applied preparation matrix commonly used in cosmetics or dermatology comprises one or more of water, emulsifier, oil, emollient, humectant, thickener, polyalcohol, antiseptic, chelating agent, and essence.
Preferably, the composition comprises the following components in percentage by mass:
0.0045 to 0.33 percent of hydrolyzed mangosteen extract;
0.001-0.18% of yeast/zinc fermentation product;
0.001-0.18% of a magnolol and honokiol compound;
0.5-10.0% of oat bran extract;
1.0-7.0% of a peppermint extract;
1.0-6.0% of ginger root extract;
the balance is the common external preparation base in cosmetics or dermatology.
Preferably, the composition comprises the following components in percentage by mass:
0.0045-0.275% of the hydrolyzed mangosteen extract;
0.001-0.15% of yeast/zinc fermentation product;
0.001-0.15% of magnolol and honokiol compound;
0.5-6.0% of oat bran extract;
1.0-6.0% of a peppermint extract;
1.0-5.0% of ginger root extract;
the balance is the common external preparation base in cosmetics or dermatology.
Preferably, the oil emulsion also contains an ester compound, wherein the ester compound comprises polyglycerol-10 oleate, wild almond oil polyglycerol-6 esters, sorbitan palmitate and dicetyl phosphate, the ester compound has better emulsifying and dispersing properties, and the weight part ratio of the components can be polyglycerol-10 oleate: wild almond oil polyglycerol-6 esters: sorbitan palmitate: dicetyl phosphate (15-20), (20-28), (3-4) and (3-4). (these are merely examples and are not intended to be limiting)
Preferably, the oat bran extract is a glycerol/propylene glycol extract solution of oat bran.
Preferably, the mentha piperita extract is an aqueous mentha piperita extract.
Preferably, the ginger root extract is a glycerol/water extract of ginger root.
Preferably, the composition is in a form of a preparation acceptable to human, preferably cream, emulsion, gel or aqua.
The composition of the present invention can be directly applied to the local skin surface, can also be added into cosmetics or medicaments for reuse, has the effects of relieving sensitivity, preventing redness and erythema, relieving itching, relieving pain and inhibiting inflammation, and can be used for preventing and treating abnormal skin symptoms such as allergy, inflammation and the like.
The invention has the beneficial effects that:
the skin care product is compounded by multiple natural plant extracts, multiple components interact with each other, the influence of external factors and irritant functional raw materials on the skin is efficiently solved from three directions of inhibiting the generation of inflammatory factors, inhibiting the release of inflammatory mediators and providing peptides required by the skin, and a skin barrier is established, so that the effects of high efficiency, allergy relief and inflammation resistance are achieved.
Drawings
Fig. 1 is a graph of skin condition of an experimental white-out experimental group (left) and an experimental group of example 1 (right).
Fig. 2 is a graph showing the evaluation results of the second experiment using example 2 and comparative example 2 after shaving.
Detailed Description
The present invention will be described in further detail with reference to specific examples, but the embodiments of the present invention are not limited thereto.
The invention provides a high-efficiency allergy-relieving and anti-inflammatory composition which has the effects of relieving sensitivity, preventing redness and erythema, relieving itching, relieving pain and inhibiting inflammation, takes a hydrolytic mangosteen extract, a yeast/zinc fermentation product, a magnolol and honokiol compound, an oat bran extract, a peppermint extract and a ginger root extract as main active ingredients, and is added with a common external preparation substrate in cosmetics or dermatology.
Allergy-relieving and anti-inflammatory cream:
the high-efficiency allergy-relieving and anti-inflammatory cream comprises the following components in percentage by mass:
the preparation method comprises the following steps:
1) mixing the hydrolyzed mangosteen extract, yeast/zinc fermentation product, magnolol, honokiol and a proper amount of ester compound to form a compound composition A, wherein the ester compound consists of polyglycerol-10 oleate, wild almond oil polyglycerol-6 esters, sorbitan palmitate dicetyl phosphate and water;
2) heating the oil phase and the water phase to 75 deg.C respectively, mixing the two phases, homogenizing for several minutes, stirring, cooling to 45 deg.C, adding compound composition A, oat bran extract, herba Menthae extract, rhizoma Zingiberis recens root extract, and antiseptic (conventional in the art), stirring, and standing at 35 deg.C to obtain brown yellow, fine and uniform paste.
The ester compound can be a self-made or commercially available product, and in this embodiment, a commercially available ester compound product is used, as follows.
The oat bran extract may be a self-made or commercially available product, and in this example, a commercially available oat bran extract product is a glycerol/propylene glycol extract solution of oat bran in a brown-yellow transparent liquid, which is merely exemplary and not intended to be limiting.
The mentha piperita extract can be a self-made or commercially available product, and in this embodiment, a commercially available mentha piperita extract product is used, and is an aqueous mentha piperita extract liquid, which is an amber transparent liquid in appearance, and the description is only illustrative and not restrictive.
The ginger root extract may be a self-made or commercially available product, and in this embodiment, a commercially available ginger root extract product is used, which is a glycerol/water extraction solution of ginger root, and the appearance is a transparent liquid, which is merely exemplified herein, but not limited thereto, and the following is the same.
After-shave gel:
the high-efficiency allergy-relieving and anti-inflammatory gel after shave comprises the following components in percentage by mass:
the preparation method comprises the following steps:
1) mixing the hydrolyzed mangosteen extract, yeast/zinc fermentation product, magnolol, honokiol and a proper amount of ester compound to form a compound composition A, wherein the ester compound consists of polyglycerol-10 oleate, wild almond oil polyglycerol-6 esters, sorbitan palmitate dicetyl phosphate and water;
2) heating phase A to 80 deg.C, homogenizing, stirring, cooling to 45 deg.C, adding composite composition A, oat bran extract, Mentha piperita extract, rhizoma Zingiberis recens root extract, and antiseptic (conventional antiseptic in the art), stirring, and standing at 35 deg.C to obtain brown yellow gel.
The allergy-relieving and anti-inflammatory mask comprises:
the high-efficiency allergy-relieving and anti-inflammatory mask comprises the following components in percentage by mass:
1) mixing the hydrolyzed mangosteen extract, yeast/zinc fermentation product, magnolol, honokiol and a proper amount of ester compound to form a compound composition A, wherein the ester compound consists of polyglycerol-10 oleate, wild almond oil polyglycerol-6 esters, sorbitan palmitate dicetyl phosphate and water;
2) heating phase A to 80 deg.C, homogenizing, stirring, cooling to 45 deg.C, adding composite composition A, oat bran extract, Mentha piperita extract, rhizoma Zingiberis recens root extract, and antiseptic (conventional antiseptic in the art), stirring, and standing at 35 deg.C to obtain brown yellow liquid.
Allergy-relieving and anti-inflammatory essence milk:
the high-efficiency allergy-relieving and anti-inflammatory essence milk comprises the following components in percentage by mass:
1) mixing the hydrolyzed mangosteen extract, yeast/zinc fermentation product, magnolol, honokiol and a proper amount of ester compound to form a compound composition A, wherein the ester compound consists of polyglycerol-10 oleate, wild almond oil polyglycerol-6 esters, sorbitan palmitate dicetyl phosphate and water;
2) respectively heating phase A and phase B to 80 deg.C, mixing, homogenizing, adding arginine water solution, cooling to 45 deg.C, adding PEG/PPG-17/6 copolymer, composite composition A, oat bran extract, Mentha piperita extract, rhizoma Zingiberis recens root extract, and antiseptic (conventional in the art), stirring, cooling to 35 deg.C, and making into light brown yellow fine emulsion.
The following experiments further illustrate the effect of the compositions of the present invention:
experiment one-histamine application test
1.1 Experimental methods: 30 volunteers, female volunteers between the ages of 20 and 45, all skin types were mixed tolerant, no allergic constitution, no skin treatment, cosmetic and other tests that may affect the outcome. The measuring area marks are made on the outer sides of the forearms of the two hands of the testee, and the areas are spaced by 1 cm. For arm testing, three 5x5cm fixation areas on the anterior side of the arm were included, two of which were compared to the control sample area and the other was blank. Dripping 1% histamine hydrochloride on arm skin in blank control area, and allowing histamine solution to be absorbed by skin with disposable sterilized pricker, wherein swelling and itching appear within 5-120 min; the same prick method was used to apply histamine to the arm in the two comparative sample areas, and then the latex finger cuffs were used to apply 0.5g + -0.1 mg sample/cm 2 for the skin itching, redness and swelling in the comparative sample areas within 5-120 minutes.
1.2 the experimental results and analyses are as follows:
table 1: remarks on the condition that the skin of the experimenter is itchy and red and swollen within 15-120 minutes are made: the data in table 1 above were processed using a rounding process to obtain processed percentage integers.
As can be seen from the above table, the person who used example 1 and had reduced itching and redness after 30min accounted for 60%, had no itching sensation after 120min, but had a slight redness and swelling, whereas the person who used comparative example 1 and had reduced itching and redness and swelling only after 90 min.
As can be seen from the comparison chart of figure 1, the allergy-relieving and anti-inflammatory cream added with the traditional Chinese medicine can effectively relieve the itching and red swelling caused by histamine.
Experiment two-post-shave allergy-relief anti-inflammatory test
2.1 Experimental methods: 30 volunteers, male volunteers between the ages of 20-45, all skin types were mixed tolerant, no allergic constitution, no skin treatment, cosmetic and other tests that may affect the outcome. Half of the test subjects used after shaving were each coated with the test substance of example 2 with the addition of the present invention and half of the test subjects used after shaving were each coated twice a day with a test substance of 1 g. + -. 0.1mg of sample/cm 2 for one month.
2.2 results and analysis of the experiment are as follows:
after one month of testing, 15 testers considered that the tingling sensation was relieved after the beard using example 2, and the skin became softer and more moisturizing; whereas only 6 of the test persons using comparative example 2 felt less noticeable as stinging.
It can be seen from fig. 2 that the addition of the after-shave gel of the present invention using example 2 is superior in all respects to the use of the after-shave gel of comparative example 2.
Experiment III-allergy-relieving anti-inflammatory Effect test
3.1 Experimental methods: the skin types of 30 male and female volunteers aged between 20 and 60 years are sensitive skins, the skins are easy to turn red, pruritus, pain and the like, and the test parts do not receive skin treatment, beautification and other tests which can influence the results. The testers were divided into three groups of 10 men and women, each numbered A, B, C. A. B, C example 3, example 4 and comparative example 3 were used separately, with a test period of 4 weeks, and the samples were applied three days per week, each time for 15 minutes followed by rinsing with clear water and application of example 5.
3.2 the results and analysis of the experiment are as follows:
table 2: statistics of test results for each group after 4 weeks
As can be seen from the above table, the subjects who used examples 3 and 4 considered improvement in skin itching, redness, pain, etc., in most cases, and the improvement using example 3 was superior to that using example 4.
It should be understood that the above-mentioned drawings are merely illustrative of the preferred embodiments of the present invention, and that the scope of the invention is not limited thereto.
Claims (9)
1. A high-efficiency allergy-relieving and anti-inflammatory composition is characterized by comprising a hydrolyzed mangosteen extract, a yeast/zinc fermentation product, a magnolol and honokiol compound, an oat bran extract, a peppermint extract and a ginger root extract.
2. The highly effective allergy-relieving and anti-inflammatory composition according to claim 1, which comprises the following components in percentage by mass:
0.0045 to 0.33 percent of hydrolyzed mangosteen extract;
0.001-0.18% of yeast/zinc fermentation product;
0.001-0.18% of a magnolol and honokiol compound;
0.1-10% of oat bran extract;
0.1-7.0% of peppermint extract;
0.1-6.0% of ginger root extract;
the balance is the common external preparation base in cosmetics or dermatology.
3. The highly effective allergy-relieving and anti-inflammatory composition according to claim 2, which comprises the following components in percentage by mass:
0.0045 to 0.33 percent of hydrolyzed mangosteen extract;
0.001-0.18% of yeast/zinc fermentation product;
0.001-0.18% of a magnolol and honokiol compound;
0.5-10.0% of oat bran extract;
1.0-7.0% of a peppermint extract;
1.0-6.0% of ginger root extract;
the balance is the common external preparation base in cosmetics or dermatology.
4. The high-efficiency allergy-relieving and anti-inflammatory composition according to claim 3, which comprises the following components in percentage by mass:
0.0045-0.275% of the hydrolyzed mangosteen extract;
0.001-0.15% of yeast/zinc fermentation product;
0.001-0.15% of magnolol and honokiol compound;
0.5-6.0% of oat bran extract;
1.0-6.0% of a peppermint extract;
1.0-5.0% of ginger root extract;
the balance is the common external preparation base in cosmetics or dermatology.
5. The highly potent, soothing anti-inflammatory composition according to any one of claims 1 to 4, further comprising an ester complex comprising polyglyceryl-10 oleate, polyglyceryl-6 amygdala oil, sorbitan palmitate and dicetyl phosphate.
6. The highly potent, allergy-relieving and anti-inflammatory composition according to any of claims 1 to 4, wherein the oat bran extract is a glycerol/propylene glycol extract solution of oat bran.
7. The highly potent allergy-relieving and anti-inflammatory composition according to any one of claims 1 to 4, wherein the Mentha piperita extract is an aqueous extract of Mentha piperita.
8. The highly potent, allergy-relieving and anti-inflammatory composition according to any of claims 1 to 4, wherein the ginger root extract is a glycerol/water extract of ginger root.
9. The highly effective allergy-relieving and anti-inflammatory composition according to any one of claims 1 to 4, wherein the composition is cream, emulsion, gel or aqua.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110203870.9A CN113018235A (en) | 2021-02-24 | 2021-02-24 | High-efficiency allergy-relieving and anti-inflammatory composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110203870.9A CN113018235A (en) | 2021-02-24 | 2021-02-24 | High-efficiency allergy-relieving and anti-inflammatory composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113018235A true CN113018235A (en) | 2021-06-25 |
Family
ID=76460976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110203870.9A Pending CN113018235A (en) | 2021-02-24 | 2021-02-24 | High-efficiency allergy-relieving and anti-inflammatory composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113018235A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105708757A (en) * | 2016-02-17 | 2016-06-29 | 佛山市芊茹化妆品有限公司 | Antiallergic microemulsion |
| CN106560178A (en) * | 2015-10-01 | 2017-04-12 | 广东工业大学 | Compositions containing magnolol, honokiol and nonsteroidal antiinflammatory drug, and applications thereof |
| CN110200830A (en) * | 2019-05-23 | 2019-09-06 | 广州科斯曼生物科技有限公司 | A kind of anti-inflammatory Shu Min remediation composition and its preparation method and application |
| CN111568780A (en) * | 2020-05-09 | 2020-08-25 | 广东华辰凯太健康管理有限公司 | Herbal gel with myotonin and preparation method thereof |
-
2021
- 2021-02-24 CN CN202110203870.9A patent/CN113018235A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106560178A (en) * | 2015-10-01 | 2017-04-12 | 广东工业大学 | Compositions containing magnolol, honokiol and nonsteroidal antiinflammatory drug, and applications thereof |
| CN105708757A (en) * | 2016-02-17 | 2016-06-29 | 佛山市芊茹化妆品有限公司 | Antiallergic microemulsion |
| CN110200830A (en) * | 2019-05-23 | 2019-09-06 | 广州科斯曼生物科技有限公司 | A kind of anti-inflammatory Shu Min remediation composition and its preparation method and application |
| CN111568780A (en) * | 2020-05-09 | 2020-08-25 | 广东华辰凯太健康管理有限公司 | Herbal gel with myotonin and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 海南美丽田园医疗健康产业有限公司: "肌喻特安倍护舒缓精华露", 《国家药品监督管理局 数据查询》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108186472B (en) | Anti-allergy relieving composition, anti-allergy relieving emulsion and preparation method of anti-allergy relieving emulsion | |
| CN110090190B (en) | Soothing cooling liquid for baby plants and preparation method thereof | |
| CN108452275A (en) | It is a kind of to have effects that the composition, medicament and preparation method of relaxing tendons and activating collaterals | |
| US20090098213A1 (en) | Pain relief and soothing cream and method for making same | |
| CN110638727B (en) | Infant hip-protecting composition and preparation method and application thereof | |
| CN113842340B (en) | Antibacterial itching-relieving, red-fading and acne-removing repairing composition and application thereof | |
| CN112569152B (en) | Oil-control anti-inflammatory plant combined extract and preparation method and application thereof | |
| KR20130015339A (en) | Cream composition for treating acne | |
| WO2024045952A1 (en) | Recombinant collagen-containing composition having effects of repairing and soothing, eye cream containing same, preparation method therefor, and use thereof | |
| CN106727032A (en) | A kind of multi-functional hydrosol and preparation method thereof | |
| CN103751530B (en) | The extract of a kind of Chinese medicine composition with anti-quick effect and application thereof | |
| KR102330465B1 (en) | Composition for skin comprising pine bark extract reducing edema, cellulite, breaking down body fat, promoting blood circulation and skin cream comprising thereof | |
| CN105267866A (en) | Emulsion for treating onychomycosis and preparation method of emulsion for treating onychomycosis | |
| CN113018235A (en) | High-efficiency allergy-relieving and anti-inflammatory composition | |
| CN110974861A (en) | Blumea balsamifera oil liposome | |
| KR102368646B1 (en) | Atopy treatment lotion utilizing room temperature emulsifying process | |
| CN110856708A (en) | Facial mask liquid and preparation method thereof | |
| CN113995701B (en) | Composition for removing acnes and acne marks as well as preparation method and application thereof | |
| CN114129493B (en) | Gastrodia elata washing-free antibacterial gel and preparation method and application thereof | |
| CN109331110A (en) | A kind of composition with swelling and pain relieving, medicament and preparation method | |
| CN115054566B (en) | Scalp aging resisting composition and preparation method thereof | |
| CN114209633B (en) | Anti-inflammatory and allergy-relieving repair composition and preparation method and application thereof | |
| CN106491445A (en) | A kind of male bud hydrosol and its application in wrinkle removal foot cream | |
| CN106581530A (en) | Plant saponin and cold catalyst composite antibacterial ointment | |
| KR20100060679A (en) | Composition for reducing irritation and inflammation in skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210625 |
|
| RJ01 | Rejection of invention patent application after publication |